Wrinkles and fine lines

A 2025 meta-analysis of 8 randomized trials in 1,361 patients (follow-up 16 weeks to 2 years) found tretinoin significantly improved fine wrinkles versus vehicle (mean difference 0.412, 95% CI 0.233 to 0.590). An earlier systematic review of 7 RCTs found consistent improvement in wrinkling, mottled pigmentation, and sallowness starting around 1 month and holding up to 24 months, at concentrations from 0.025% upward.

A meta-analysis of 7 randomized placebo-controlled trials with 1,474 subjects found investigator-rated response rates dramatically higher with botulinum toxin than placebo for glabellar (frown) lines, with no increase in adverse events versus placebo. A 2023 network meta-analysis of randomized trials compared the approved formulations and found all effective for moderate to severe glabellar lines. For crow's feet, two phase 3 trials totaling 1,362 patients plus a separate multicenter randomized trial showed significant improvement with a 24-unit dose, with effects lasting roughly 3 to 5 months. Frown lines, crow's feet, and forehead lines are all on-label FDA-approved uses.

A 2022 meta-analysis pooled 22 randomized controlled trials with 1,848 subjects on nasolabial fold correction and found consistent improvement in wrinkle severity scores through 52 weeks, with monophasic (smooth cohesive) gels outperforming biphasic (particle-based) gels at most timepoints. Correction of moderate folds typically holds 6 to 12 months. Nasolabial fold treatment is the on-label FDA-approved indication for most HA fillers.

A multi-site evaluation in 609 patients supported CaHA as effective and well tolerated for facial soft-tissue augmentation including nasolabial folds, the basis of its 2006 FDA approval for moderate to severe facial wrinkles and folds. A 2024 systematic review of facial use confirms a consistent efficacy and safety record across on-label indications, with correction typically lasting 12 to 18 months, longer than most HA fillers.

A 12-week randomized double-blind trial found non-prescription tri-retinol 1.1% and prescription tretinoin 0.025% produced similar improvements in fine and coarse periocular wrinkles, and a 2025 network meta-analysis ranked retinol among the more effective topicals for fine wrinkles. But a 2021 systematic review of 9 vehicle-controlled OTC retinol trials found 4 showed no significant difference from vehicle and 5 showed only weak evidence of a mild effect on fine wrinkles, so product-level evidence is much shakier than tretinoin's.

A 2023 systematic review of randomized controlled trials concluded topical vitamin C usefully improves photodamaged skin, with treated skin appearing smoother and less wrinkled than placebo-treated skin across the included vehicle-controlled trials. Trials are mostly small (dozens of patients) and 12 weeks to 6 months long, and formulations vary widely, which limits how precisely effects can be estimated.

A comparative trial found both fractional CO2 and Er:YAG produce considerable improvement in facial wrinkles without serious adverse events, and a 2025 expert consensus supports it as a standard tool for facial photoaging. Most wrinkle data comes from split-face and comparative trials rather than large sham-controlled RCTs, which is hard to run for an ablative device, so the grade stays moderate despite consistent results.

For nasolabial folds, a multicenter randomized trial with 120-week follow-up compared PLLA head to head with HA filler and found different time courses: HA corrects immediately then fades, while PLLA builds more slowly and holds correction longer, out past 2 years. PLLA suits deeper folds tied to volume loss rather than fine surface lines, which it does not address well.

A 12-week double-blind, split-face randomized study in 50 women found 5% niacinamide reduced fine lines and wrinkles, red blotchiness, and sallowness versus vehicle. The improvements were measurable but small, the studies were industry-run, and independent replication is lacking, so it is best viewed as a supporting ingredient rather than a primary wrinkle treatment.

In a double-blind, vehicle-controlled trial of 74 women aged 40 to 70, 8% glycolic acid cream was modestly useful against signs of photodamage over 22 weeks, a finding the authors themselves phrased cautiously. Marketing for home glycolic products implies peel-level resurfacing; the controlled data show small improvements in fine lines at OTC strengths.

Small studies report measurable wrinkle-depth reductions: up to 40% at 8 weeks with a nano-HA formulation, and significant roughness improvements with 50 and 130 kDa HA creams over 60 days. These effects come substantially from hydration-driven plumping, reverse when you stop, and have not been tested in large independent vehicle-controlled trials. Marketing routinely equates this with injectable HA filler results, which it is not.

In the key RCT, 44 patients used bakuchiol 0.5% twice daily or retinol 0.5% nightly for 12 weeks: both significantly reduced wrinkle surface area with no statistical difference between them, and bakuchiol users reported less scaling and stinging. A 2022 systematic review found consistent improvements in photodamage and wrinkle scores across the small clinical literature. One adequately designed comparative trial is promising but not yet strong evidence.

Anti-aging evidence is far weaker than the acne scar data. A randomized trial of 20 women aged 35 to 60 who got 4 monthly sessions found measurable texture improvement, with larger gains when growth factor serums were added, but trials this small cannot support the sweeping rejuvenation claims made in marketing. No large RCT has compared microneedling against established wrinkle treatments like retinoids or resurfacing lasers.

Reviews report improvement in periorbital and lower-face wrinkles, but wrinkle-specific outcomes mostly come from small prospective studies with subjective grading scales rather than blinded RCTs against proven comparators. The technology plausibly helps texture and fine lines through the same collagen mechanism, but the wrinkle data is weaker than the acne scar data and weaker than device marketing implies.

A 2021 systematic review of 16 studies (637 participants, average 4.3 sessions) reported improvements in texture, pores, and fine rhytids alongside the stronger vascular and pigment effects, but most included studies were uncontrolled with subjective grading. IPL delivers gentle collagen stimulation at best; it does not approach fractional laser resurfacing for established wrinkles, despite photorejuvenation branding.

Wrinkle outcomes in HIFU studies are secondary measures folded into overall rejuvenation scores rather than primary endpoints, and the pooled improvement in the 2020 meta-analysis was moderate. HIFU works at depths below where fine surface lines live, so it is a poor match for etched-in wrinkles compared with resurfacing approaches.

One randomized controlled trial found red light photobiomodulation reduced periocular wrinkle volume by about 30 percent (31.6 percent for red, 29.9 percent for amber), and reviews report texture improvements. But the trials are small, follow-up is short (benefits in one study faded within about a month of stopping), and there is no evidence LED approaches retinoids, peels, or lasers for established wrinkles. Consumer mask marketing substantially overstates this data.

A 2021 systematic appraisal of 36 studies (3,172 patients) found the clinical evidence for PRP facial rejuvenation very limited, dominated by uncontrolled studies with inconsistent PRP preparation. A 2025 systematic review of 11 studies reported improvements in wrinkles, texture, and hydration in several trials, but sample sizes stay small and blinding is rare. Plausible modest benefit, unproven against standard treatments.

Skin boosters soften fine surface lines as a byproduct of hydration; the VYC-12L randomized trial included fine lines among improved endpoints. They do not lift folds or treat expression lines, and anyone with moderate to deep wrinkles will get clearly more from botulinum toxin or conventional filler. For fine crepey lines the effect is genuine but small and temporary.

A 2026 systematic review and meta-analysis of human clinical trials in aesthetic medicine reported average facial wrinkle reduction of 20.2 percent and improvements of 14.7 to 23.4 percent across elasticity, texture, and pigmentation endpoints, with few adverse events. The catch: included trials were small, follow-up was short, products varied wildly in source and content, and many protocols paired exosomes with microneedling or laser, which improve skin on their own. A separate 2026 systematic review reached the same conclusion: promising signals, but standardized controlled trials are still missing.